Do You Really Need Supplements During Menopause?

More than half of women in menopause report taking dietary supplements to manage symptoms, but experts say most lack solid evidence of benefit—and some may pose risks. According to a 2024 analysis by the French National Authority for Health (Haute Autorité de Santé, HAS), only three supplements—calcium, vitamin D, and possibly omega-3 fatty acids—have “moderate” support for symptom relief or bone health during this stage. The rest, including popular options like black cohosh, red clover, or soy isoflavones, remain unproven or carry potential side effects.

The HAS review, published in June 2024, found that while 62% of French women aged 45–60 use supplements during menopause, fewer than 20% consult a healthcare provider before starting them. “Many women turn to supplements out of desperation for symptom relief, but the evidence doesn’t always match the marketing claims,” said Dr. Sophie Marceau, an endocrinologist at the Paris Public Health Institute (Institut de Santé Publique de Paris). She noted that even calcium and vitamin D—widely recommended—should only be taken if dietary intake is insufficient, as excess doses can cause kidney stones or interfere with other medications.

Black cohosh, often promoted for hot flashes, has shown mixed results in clinical trials. A 2023 meta-analysis in the Journal of the North American Menopause Society concluded that while some studies reported modest benefits, others found no effect compared to placebo. The HAS warned that black cohosh may interact with liver-metabolized drugs, including certain antidepressants and blood thinners. Similarly, red clover supplements—marketed for mood and bone support—lacked consistent evidence in a 2022 Cochrane Review, which flagged potential hormone-like effects that could worsen estrogen-sensitive conditions.

Omega-3s, however, stand out as the only supplement with emerging support. A 2023 randomized trial in Menopause: The Journal found that women taking 2 grams daily of EPA/DHA experienced a 30% reduction in severe hot flashes after 12 weeks, with no serious side effects. Yet even here, experts caution that results vary by individual, and the optimal dosage remains unclear. “Omega-3s are promising, but they’re not a magic bullet,” said Dr. Elena Rodriguez, a menopause specialist at the Spanish Society of Gynecology and Obstetrics (SEGO). “They should be part of a broader strategy that includes diet, exercise, and, when needed, hormone therapy.”

The HAS review also highlighted a gap in regulation: supplements in France and many European countries are classified as foods, not drugs, meaning they undergo minimal pre-market scrutiny. Unlike prescription medications, manufacturers are not required to prove efficacy before selling products. “This creates a wild west scenario where women are making decisions based on anecdotes or social media rather than science,” said Marceau. The authority recommended that women prioritize evidence-based approaches, such as hormone therapy for moderate-to-severe symptoms, when appropriate.

For those who choose supplements, the HAS advised selecting products tested by independent labs (e.g., NSF International or Informed-Choice) and starting with the lowest effective dose. “The supplement industry preys on fear and uncertainty,” said Rodriguez. “Women deserve transparency—not just about what’s in the bottle, but about what the science actually says.”

Why this matters: Menopause affects over 1 billion women globally, yet many lack access to reliable guidance. While supplements may offer temporary relief for some, the HAS review underscores the need for better education and stricter oversight. In the U.S., the Food and Drug Administration (FDA) has similarly warned against unproven menopause supplements, citing cases of contamination and misleading claims. Meanwhile, the World Health Organization (WHO) has called for standardized global guidelines on menopause management, emphasizing that supplements should never replace proven therapies.

What remains uncertain is how regulatory bodies will respond. The European Commission is currently evaluating proposals to tighten supplement labeling laws, but no major changes are expected before 2027. In the absence of stronger oversight, experts urge women to approach supplements with caution—and to treat them as a last resort, not a first line of defense.